Literature DB >> 11590850

Lung transplantation for primary pulmonary hypertension.

E P Trulock1.   

Abstract

Recent progress in medical therapies has diminished the role of transplantation in the management of PPH during the past decade. Drug therapy is not effective in some patients, responses to therapy are not sustained over time in others, and drug side effects eventually limit the benefits of treatment in a few more. Lung transplantation therefore ultimately is the only alternative for patients whose PPH is severe and cannot be managed medically. Choosing the right patient as a transplant candidate and the right time to make the initial referral to a transplant center are the crucial initial steps in the transplantation process, and the long waiting time before transplantation must be integrated into this decision. The outcome of lung and heart-lung transplantation for PHH has been good but sobering. Functional recovery has been excellent, but long-term survival results have been limited by the high prevalence of chronic allograft rejection.

Entities:  

Mesh:

Year:  2001        PMID: 11590850     DOI: 10.1016/s0272-5231(05)70293-8

Source DB:  PubMed          Journal:  Clin Chest Med        ISSN: 0272-5231            Impact factor:   2.878


  3 in total

Review 1.  Pulmonary hypertension-"state of the art" management in 2012.

Authors:  Anita Saxena
Journal:  Indian Heart J       Date:  2012-03-26

2.  Atrial septostomy in the treatment of severe pulmonary arterial hypertension.

Authors:  F Reichenberger; J Pepke-Zaba; K McNeil; J Parameshwar; L M Shapiro
Journal:  Thorax       Date:  2003-09       Impact factor: 9.139

3.  The role of extracorporeal life support in the management with severe idiopathic pulmonary artery hypertension undergoing lung transplantation: are those patients referred too late?

Authors:  Anton Sabashnikov; Prashant N Mohite; Mohamed Zeriouh; Bartlomiej Zych; Diana García-Sáez; Johanna Maier; Alexander Weymann; Javid Fatullayev; Balakrishnan Mahesh; Aron-Frederik Popov; Ulrich Stock; Fabio De Robertis; Toufan Bahrami; Thorsten Wahlers; Martin Carby; André R Simon; Anna Reed
Journal:  J Thorac Dis       Date:  2019-04       Impact factor: 2.895

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.